Reaction profile

The FDA adverse-event record for prostatic tumour

Name: Prostatic tumour - FDA Animal Adverse Reaction
Creator: PlainBreed
License: https://open.fda.gov/license/

27 FDA reports name prostatic tumour, a lower-volume reaction in the CVM extract (VeDDRA 794). Plate stamps and neighbourhood peers follow.

#2046 of 2,481
by report volume (all reactions): 27
reports citing this reaction: 59.3%
death-coded share: Dog
most-affected species

Compiled by PlainBreed

Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Prostatic tumour has 27 reports now versus 26 in that prior snapshot: 1 more (3.8%).

Report change: +1
Death-coded reports: +0
Death-coded share: −2.3 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Prostatic tumour changes

FDA AER · VeDDRA plate

Code 794 VOL-TRACE

VOL-TRACE · DEATH-HOT · LOWER-Q · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

VOL-TRACE 27 reports
DEATH-HOT 59.3%
LOWER-Q #2046/2481
PHOTO-FINISH Abortion spontaneous
SPECIES-DOG Dog · 27
DRUG-LEAD Oclacitinib Malea… · 7
DESK-WIDE 20 breeds
BOOK-FULL 8/8 fields

Nearest volume peer: Abortion spontaneous (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Lower-volume neighbourhood around Prostatic tumour

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

FDA AER report volume · neighbourhood around Prostatic tumour

Prostatic tumour: high death-coded share in the FDA AER plate

Signature read: Prostatic tumour's 59.3% death-coded share is among the highest in the openFDA reaction corpus. Report volume is lower-third scale: 27 named reports in the openFDA extract. Death-coded share is upper-third: 16 of 27 reports (59.3% of named reports). Nearest volume peer: Abortion spontaneous (±0 reports). Lead species Dog (27). Lead co-reported drug Oclacitinib Maleate (7).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 27

Breeds Most Affected

Dog (unknown) 3

Retriever - Labrador 3

Boxer (German Boxer) 2

Retriever - Golden 2

Spaniel - Springer English 2

Poodle (unspecified) 1

Dachshund (unspecified) 1

Crossbred Canine/dog 1

Beagle 1

Shepherd Dog - Belgian Malinois 1

Associated Drugs

Oclacitinib Maleate 7

Trilostane 4

Milbemycin Oxime + Spinosad 3

Gabapentin 3

Prednisone 2

Imidacloprid + Moxidectin 2

Deracoxib 2

Ivermectin + Pyrantel As Pamoate Salt 2

Carprofen 2

Cyclosporine 2

Grapiprant 2

Bedinvetmab 2

Joint Supplement 2

Spinosad 1

Cephalexin 1

Diphenhydramine 1

Lyme Vaccine 1

Cefovecin 1

Tramadol 1

Enrofloxacin 1

What to do with this reaction

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full reaction directory to compare report counts across reaction types. All reactions

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Prostatic tumour (#2046 of 2,481 by report volume); death-coded 59.3%. PlainBreed reaction plate · death-coded share stamp 59.3% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →